Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC88 in advanced solid tumors
NCT04175847Phase 2Completed
- Sponsor
- RemeGen
- Start
- Apr 2020
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of misitatug blivedotin in malignant pleural mesothelioma (MPM), ovarian carcinoma, pancreatic cancer (PC), gastric adenocarcinoma, triple-negative breast cancer (TNBC), sponsored by RemeGen. Started Apr 2020; status: completed.
02
Drugs
misitatug blivedotin
03
Conditions
malignant pleural mesothelioma (MPM)ovarian carcinomapancreatic cancer (PC)gastric adenocarcinomatriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04175847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175847.